Shukra Pharmaceuticals Ltd (SHUKRAPHAR) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Shukra Pharmaceuticals Ltd on NSE and BSE, with an AI summary of each filing.
Shukra Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.
Outcome · 05 Nov 2026, 2:22 am
Reg 32
Others (Uncategorized) · 05 Nov 2026, 2:18 am
Shukra Medtech Reports Zero Deviation in Preferential Issue Fund Utilization Shukra Medtech Limited confirmed zero deviation or variation in utilizing funds raised via 46.43 lakh convertible warrants issued on a preferential basis. The company received 75% of the consideration totaling ₹10.46 cr across 14th Jul'26 and 2nd Sep'26. As of the quarter ended 30th Sep'26, the entire ₹10.46 cr proceeds were fully deployed as planned: ₹5.76 cr for working capital and bank guarantee margins, ₹4.23 cr for capex in subsidiary companies, and ₹0.45 cr toward general corporate purposes, with no modifications to original objectives.
Unaudited financial results for the quarter ended 30th September 2026
Financial Result · 05 Nov 2026, 2:14 am
Unaudited financial results for the quarter ended 30th September 2026
Outcome · 05 Nov 2026, 2:10 am
Shukra Pharmaceuticals Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Lakh) ■ Revenue: 4,420 (+652.1% YoY | +87.9% QoQ) ■ EBITDA: 1,870 (Loss to Profit YoY | -2.3% QoQ) ■ EBITDA Margin (%): 42.3 (Loss to Profit YoY | -3907 bps QoQ) ■ PAT: 1,271 (+434.5% YoY | -1.9% QoQ) ■ EPS (INR): 0.29 (+480.0% YoY | -3.3% QoQ) Shukra Pharmaceuticals Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Lakh) Segmental Performance Pharmaceutical segment ■ Revenue: 3,227 (+325.2% YoY | +34.1% QoQ) ■ EBIT: 1,506 (+3016.3% YoY | -19.0% QoQ) ■ EBIT Margin (%): 46.7 (+4031 bps YoY | -3062 bps QoQ) Medtech segment ■ Revenue: 1,251 ■ EBIT: 310 ■ EBIT Margin (%): 24.8
SHUKRA PHARMACEUTICALS LIMITED has informed the Exchange about Board Meeting to be held on 04-Nov-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Quarterly ended September 2026 .
Intimation · 04 Nov 2026, 5:30 am
The Board Meeting to be held on 03/11/2026 has been revised to 04/11/2026 The Board Meeting to be held on 03/11/2026 has been revised to 04/11/2026
Intimation · 04 Nov 2026, 5:30 am
Shukra Medtech Board Meeting Scheduled for 4th Nov'26 to Consider Q2 Results Shukra Medtech Limited (formerly Shukra Pharmaceuticals Limited) has scheduled its Board of Directors meeting for 4th Nov'26 (rescheduled from 3rd Nov'26) at its registered office. The board will inter alia consider and approve the company's unaudited financial results for the second quarter and half year ended 30th Sep'26, alongside the Auditor's Limited Review Report.
SHUKRA PHARMACEUTICALS LIMITED has informed the Exchange about Board Meeting to be held on 04-Nov-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Quarterly ended September 2026 .
Intimation · 04 Nov 2026, 5:30 am
SHUKRAPHAR : 04-Nov-2026 : The Company has informed the Exchange that a Board meeting to be held on November 03, 2026 has been re-scheduled. Further, the Company has informed the Exchange that the meeting of the Board of Directors of the Company will be held on November 04, 2026, To consider and approve the financial results for the period ended September 30, 2026
Intimation · 04 Nov 2026, 5:30 am
SHUKRA PHARMACEUTICALS LIMITED has informed the Exchange about Board Meeting to be held on 03-Nov-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Quarterly ended September 2026 .
Intimation · 03 Nov 2026, 5:30 am
Shukra Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/11/2026 ,inter alia, to consider and approve Un-Audited Financial ....
Intimation · 03 Nov 2026, 5:30 am
Shukra Medtech Schedules Board Meeting to Approve Q2 Results Shukra Medtech Limited (formerly Shukra Pharmaceuticals Limited) has scheduled a Board of Directors meeting on 3rd Nov'26 at its registered office. The board will inter alia consider and approve the company's unaudited financial results for the second quarter and half-year ended 30th Sep'26, alongside the Auditor's Limited Review Report.
To consider and approve the financial results for the period ended September 30, 2026
Intimation · 03 Nov 2026, 5:30 am
Change of Name by MCA
Others (Uncategorized) · 13 Oct 2026, 12:34 am
Shukra Pharmaceuticals Receives MCA Approval for Name Change to Shukra Medtech The Ministry of Corporate Affairs approved the name change of Shukra Pharmaceuticals Limited to Shukra Medtech Limited, effective 12th Oct'26, following the issuance of a fresh Certificate of Incorporation. The rebranding is driven by business restructuring and alignment with the company’s future corporate strategy focused on technology-driven healthcare operations. The company is completing formalities with stock exchanges to update records and transition to a new trading symbol.
Allotment of Shares pursuant to conversion of Warrants
Others (Uncategorized) · 07 Oct 2026, 12:12 am
Shukra Pharmaceuticals Allots Equity Shares on Warrant Conversion Shukra Pharmaceuticals approved the allotment of 17,35,000 equity shares of Re.1/- each on 6th Oct'26 upon converting warrants held by promoter entities Ms. Anar Jayesh Patel and Anar Projects Private Limited. The allotment follows receipt of the 75% balance exercise price at Rs.26.67 per warrant, aggregating Rs.4.63 cr. Consequently, paid-up equity capital increased to Rs.44.25 cr (44,25,22,440 shares), with the combined promoter entities' holding rising from 19.70% to 20.01%. All 46,43,000 warrants allotted on 28th Jan'26 are fully converted, leaving zero outstanding warrants.
Clarification from the Company
Others (Uncategorized) · 07 Oct 2026, 12:01 am
Shukra Pharmaceuticals Clarifies Share Price Movement is Purely Market-Driven Shukra Pharmaceuticals Ltd clarified to BSE on 6th Oct'26 that recent movements in its share price are purely market-driven by natural forces, with management having no connection to the volatility. The company confirmed full compliance with SEBI LODR Regulation 30, stating that all material events, operations, and corporate actions have been disclosed timely. Additionally, the company affirmed there is no pending announcement or undisclosed price-sensitive information requiring investor disclosure at this stage.
The Exchange has sought clarification from Shukra Pharmaceuticals Ltd on October 06, 2026 with reference to significant movement in price, in order to ensure that investors have latest ....
Others (Uncategorized) · 06 Oct 2026, 10:57 pm
Voting Results and Scrutinizer''s Report
Annual General Meeting · 30 Sept 2026, 12:12 am
Shukra Pharmaceuticals Shareholders Approve All Resolutions at 33rd AGM Shukra Pharmaceuticals Limited announced the approval of all four resolutions at its 33rd AGM held on 28th Sep'26. Key approvals include the adoption of FY26 audited financial statements with 99.9981% votes in favour, declaration of a final dividend for FY26 with 99.9966% approval, and the re-appointment of executive director Ms. Sanskruti Patel with 99.8574% backing (promoters holding 51.15% were excluded). Additionally, shareholders approved the regularization of Mr. Dinesh Chauhan as an Additional Independent Director via special resolution with 99.9975% affirmative votes.
Outcome of AGM
Annual General Meeting · 28 Sept 2026, 7:58 pm
ANNUAL REPORT
Others (Uncategorized) · 06 Sept 2026, 3:07 am
AGM NOTICE
Annual General Meeting · 06 Sept 2026, 2:59 am
Update on Date of AGM
Annual General Meeting · 04 Sept 2026, 1:36 am
Intimatation of Record Date for Dividend
Dividend · 03 Sept 2026, 5:45 pm
Shukra Pharmaceuticals Limited has informed the Exchange regarding Outcome of Board Meeting held on September 02, 2026.
Outcome · 03 Sept 2026, 12:23 am
Shukra Pharmaceuticals Allots 1.17 Million Shares Upon Promoter Warrant Conversion On 2nd Sep'26, Shukra Pharmaceuticals allotted 11.73 lakh equity shares to promoter Navkar Surgical Gujarat Ltd following warrant conversion. By receiving the 75% balance of Rs.26.67 per share against the Rs.35.56 issue price, the company raised Rs.3.13 crore. Consequently, paid-up equity capital increased to Rs.44.08 crore, while Navkar's post-diluted holding rose from 11.78% to 11.93%. Following this tranche, 17.35 lakh warrants remain outstanding for future conversion from the original 28th Jan'26 preferential allotment.
Allottment of Preference Shares
Others (Uncategorized) · 03 Sept 2026, 12:19 am
Shukra Pharmaceuticals Allots 1.17M Equity Shares Upon Warrant Conversion to Promoters On 2nd Sep'26, Shukra Pharmaceuticals allotted 11,73,000 equity shares to promoter Navkar Surgical Gujarat Ltd upon warrant conversion. This follows the receipt of the balance 75% exercise price of Rs.26.67 per share, generating Rs.3.13 crore. Consequently, paid-up equity capital increased to Rs.44.08 crore, with Navkar Surgical's post-issue stake rising to 11.93%. Following this tranche, 17,35,000 warrants from the 28th Jan'26 issuance remain outstanding, convertible upon payment of the remaining 75% premium within the 18-month validity period.
AGM and Change of Name
Outcome · 22 Aug 2026, 8:20 pm
Media Release
Others (Uncategorized) · 18 Aug 2026, 12:38 am
Shukra Pharmaceuticals Lists on NSE, Signals Tech-Focused Strategy Shukra Pharmaceuticals' equity shares commenced trading on the National Stock Exchange (NSE) on 14 Aug'26, under the symbol SHUKRAPHAR. This dual listing, alongside its existing BSE presence, marks a key capital market milestone. The company highlighted its strategic direction, focusing on medical technology, artificial intelligence (AI), and healthcare innovation for future growth and diversification. The firm clarified that media coverage on this topic does not represent any new undisclosed material transaction. The company will continue to adhere to SEBI disclosure norms.